About

David Wyatt, PhD, is the Chief Executive Officer of Aston Particle Technologies and a pharmaceutical scientist with extensive medicine development experience. Dr Wyatt spent 32 years with GSK, holding a range of senior scientific and management positions spanning the development of five major new chemical entities from molecule selection to being amongst the gold standard respiratory medicines in today’s marketplace. Immediately prior to joining APT, Dr Wyatt was the Vice-President and Head of the Respiratory Centre of Excellence for New Product Introduction within GSK Manufacturing and has a broad appreciation of what it takes to champion a good idea to bring it to industrial reality.

Contributions

PULMONARY

ISOTHERMAL DRY PARTICLE COATING – BACK TO THE FUTURE?

Jasdip Koner, Abdul Ershad and David Wyatt introduce Aston Particle Technologies’ novel dry powder processing technology – isothermal dry particle coating (iDPC™) – explaining how it has the capacity to enhance and broaden the scope of what dry powder formulations can achieve in respiratory medicine.